Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.44 |
| ▸ | RORC | P51449 | 2/20 | 0.44 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.44 |
| ▸ | ATXN2 | Q99700 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4979370 | 1.00 | MEN1 (0.46) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL14674895 | 0.90 | RORC (0.42) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL6099116 | 0.88 | SMN1; SMN2 (0.46) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL6099121 | 0.88 | SMN1; SMN2 (0.46) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL3728320 | 0.88 | XIAP (0.51) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL15676882 | 0.88 | HDAC1 (0.46) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL1196005 | 0.87 | MEN1 (0.51) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL1196006 | 0.87 | MEN1 (0.51) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL1195937 | 0.87 | SMN1; SMN2 (0.42) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL1195938 | 0.87 | SMN1; SMN2 (0.42) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230416262-A1 | TRPML MODULATORS | CASMA THERAPEUTICS, INC. | 2023-12-28 | — | — | US | disclosed |
| EP-4192957-A2 | TRPML MODULATORS | Casma Therapeutics, Inc. (US) | 2023-06-14 | — | — | EP | disclosed |
| CN-116113698-A | TRPML modulators | 卡斯玛治疗公司 | 2023-05-12 | — | — | CN | disclosed |
| WO-2022032073-A2 | TRPML MODULATORS | CASMA THERAPEUTICS, INC. (US) | 2022-02-10 | — | — | WO | disclosed |
| US-20130035310-A1 | Piperidine and Piperazine Phenyl Sulfonamides as Modulators of Ion Channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-02-07 | — | — | US | disclosed |
| US-20130035310-A1 | Piperidine and Piperazine Phenyl Sulfonamides as Modulators of Ion Channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-02-07 | — | — | US | disclosed |
| EP-2316829-A1 | Heterocyclic derivatives as modulators of ion channels | Vertex Pharmaceuticals Incorporated (US) | 2011-05-04 | — | — | EP | disclosed |
| US-7354925-B2 | Alpha aryl or heteroaryl methyl beta piperidino propanamide compounds as ORL1-receptor antagonists | PFIZER INC. (US) | 2008-04-08 | — | — | US | disclosed |
| US-7279486-B2 | Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as ORL1-receptor antagonists | PFIZER INC. (US) | 2007-10-09 | — | — | US | disclosed |
| US-20070197500-A1 | 3-(2,3-Dihydro-1'H-spiro[indene-1,4'-piperidin]-1'-yl)-N,N-dimethyl-2-(pyridin-2-ylmethyl)propanamide; opioid receptor-like 1 antagonist; reduced inhibitory activity at HERG potassium channel; analgesic; side effect reduction; neurpathic and other pain | PFIZER, INC. | 2007-08-23 | — | — | US | disclosed |
| US-20050277659-A1 | Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as ORL1-receptor antagonists | PFIZER JAPAN INC. (JP) | 2005-12-15 | — | — | US | disclosed |
| US-6013652-A | ANTIINFLAMMATORY AGENTS; ANALGESICS; ANTIHISTAMINES | MERCK & CO., INC. (US) | 2000-01-11 | — | — | US | disclosed |
| US-5962462-A | COMPOUNDS WHICH INHIBIT THE ENTRY OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INTO TARGET CELLS; DELAYING THE ONSET OF ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS). | MERCK & CO., INC. (US) | 1999-10-05 | — | — | US | disclosed |
| WO-1998025605-A1 | SPIRO-SUBSTITUTED AZACYCLES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 1998-06-18 | — | — | WO | disclosed |
| EP-0702681-A1 | SPIRO-SUBSTITUTED AZACYCLES AS NEUROKININ ANTAGONISTS | MERCK & CO. INC. (US) | 1996-03-27 | — | — | EP | disclosed |
| WO-1994029309-A1 | SPIRO-SUBSTITUTED AZACYCLES AS NEUROKININ ANTAGONISTS | MERCK & CO., INC. (US) | 1994-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277659-A1 | Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as ORL1-receptor antagonists | OPRL1, OGFRL1, ORMDL3 | MEN1 3648/4885KMT2A 2040/4885NPSR1 481/4885 |
| US-20130035310-A1 | Piperidine and Piperazine Phenyl Sulfonamides as Modulators of Ion Channels | TRPV1, TRPV5, TRPA1 | MEN1 4701/4885KMT2A 1129/4885NPSR1 287/4885 |
| US-20070197500-A1 | 3-(2,3-Dihydro-1'H-spiro[indene-1,4'-piperidin]-1'-yl)-N,N-dimethyl-2-(pyridin-2-ylmethyl)propanamide; opioid receptor-like 1 antagonist; reduced inhibitory activity at HERG potassium channel; analgesic; side effect reduction; neurpathic and other pain | OPRL1, OPRD1, OPRK1 | MEN1 3875/4885KMT2A 2103/4885NPSR1 192/4885 |
| US-20230416262-A1 | TRPML MODULATORS | TRPM2, TRPM4, TRPM5 | MEN1 782/4885KMT2A 2892/4885NPSR1 508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.